34. The method of claim 30 or 33, wherein emulsifying the coarse emulsion comprises using a high pressure homogenizer.

35. The method of claim 34, wherein emulsifying the primary emulsion comprises about 2 to about 3 passes through the homogenizer.

36. The method of claim 34 or 35, wherein the homogenizer feed pressure is about 2000 to about 8000 psi per interaction chamber.

37. The method of any one of claims 34-36, wherein the homogenizer comprises multiple interaction chambers.

38. The method of any one of claims 28-37, wherein quenching is at least partially performed at a temperature of about 5 °C or less.

39. The method of any one of claims 28-37, wherein quenching is performed at about 0 °C to about 5 °C and wherein the quench:emulsion ratio is about 2:1 to about 40:1.

40. The method of any one of claims 28-39, wherein the quench: emulsion ratio is about 2:1 to about 40:1.

41. The method of any one of claims 28-39, wherein the quench: emulsion ratio is about 5:1 to about 15:1.

42. The method of any one of claims 29-41, wherein the drug solubilizer is selected from the group consisting of Tween 80, Tween 20, polyvinyl pyrrolidone, cyclodextran, sodium dodecyl sulfate, and sodium cholate.

43. The method of any one of claims 29-41, wherein the drug solubilizer is selected from the group consisting of diethylnitrosamine, sodium acetate, urea, glycerin, propylene glycol, glycofurol, poly(ethylene)glycol, bris(polyoxyethyleneglycolddodecyl ether, sodium benzoate, and sodium salicylate.

44. The method of any one of claims 29-43, wherein the ratio of drug solubilizer to therapeutic agent is about 200:1 to about 10:1.

45. The method of any one of claims 1-44, wherein filtration comprises tangential flow filtration.

46. The method of any one of claims 1-45, wherein filtration comprises filtering at a first temperature of about 0 °C to about 5 °C.